TOWARDS NEW HEIGHTS AFTER A PROFITABLE AND INTENSE QUARTER

Revenues in the first quarter of 2024 amounted to SEK 454.5 (393.7) million, corresponding to 15% (18%) growth compared to the corresponding period last year. EBITDA increased to SEK 51.7 (40.8) million and the EBITDA margin to 11.4% (11.3%). During the quarter, a strategic partnership in Europe was entered into with the North American direct sales company ACN, which also invested in 149,468 Zinzino B shares via a directed share issue of SEK 10.4 million. After the end of the period, Zinzino acquired the rights to the Luxembourg-based Xelliss SA distributor database, inventory and IP assets. The fixed purchase price amounts to EUR 2 million and conditional additional purchase prices of up to EUR 8 million may be added.

JANUARY-MARCH

** Total revenue amounted to SEK 454.5 (393.7) million, corresponding to a growth of 15% (18%)
** Gross profit amounted to SEK 160.9 (130.7) million and the gross profit margin amounted to 35.4% (33.2%)
** EBITDA amounted to SEK 51.7 (44.4) million and the EBITDA margin amounted to 11.4% (11.3%)
** Cash flow from operating activities amounted to SEK 3.1 (65.0) million
** Cash and cash equivalents amounted to SEK 328.1 (216.4) million on the balance sheet date

Link to the report:
https://www.zinzino.com/site/GB/en-GB/about/investor-relations/

For more information please contact:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, email: dag@zinzino.com
Fredrik Nielsen CFO Zinzino +46 707 900 174, email: fredrik.nielsen@zinzino.com

Images for free publication:
marketing@zinzino.com

Certified Adviser: Carnegie Investment Bank AB (publ.)

This information is information that Zinzino AB (publ.) is obliged to make public according to the EU's market abuse regulation. The information was provided by the above contact person for publication at 08.00 on 22 May 2024.

Zinzino is a global direct sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their scientifically proven nutritional supplements are available on more than 100 markets across the world. Zinzino owns the Swiss, biotech skincare brand HANZZ+HEIDII, as well as the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden with additional offices in Europe, Asia, the US and Australia.

https://news.cision.com/zinzino/r/zinzino-ab--publ--interim-report-first-quarter-2024,c3985260

https://mb.cision.com/Public/10976/3985260/b2c99755faa75b7c.pdf

(c) 2024 Cision. All rights reserved., source Press Releases - English